Floatz logo

nxp800

Ovarian Clear Cell Carcinoma

Nuvectis Pharma, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Ovarian Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
Genelux Corporation
Phase 3BB
Carboplatin
Genelux Corporation
Phase 3BB
Docetaxel
Genelux Corporation
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3B
Olvimulogene Nanivacirepvec
Genelux Corporation
Phase 3B

View all 20 →

Same molecule, other indications

nxp800 is also rated in:

ovarian clear cell tumorDormant
CC
Indicative ·
43 / 100
View asset →
ovarian clear cell adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ARID1A Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →